X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (957) 957
male (836) 836
indazoles - pharmacology (751) 751
humans (606) 606
index medicus (564) 564
rats (547) 547
indazoles - administration & dosage (454) 454
female (399) 399
mice (371) 371
enzyme inhibitors - pharmacology (334) 334
pharmacology & pharmacy (321) 321
nitric oxide (306) 306
nitric oxide synthase - antagonists & inhibitors (291) 291
oncology (260) 260
indazoles - therapeutic use (242) 242
neurosciences (237) 237
middle aged (225) 225
rats, sprague-dawley (217) 217
dose-response relationship, drug (200) 200
7-nitro indazole (178) 178
adult (177) 177
aged (173) 173
rats, wistar (170) 170
indazoles - adverse effects (152) 152
7-nitroindazole (140) 140
ng-nitroarginine methyl ester - pharmacology (129) 129
indazoles - pharmacokinetics (128) 128
administration, oral (126) 126
cancer (124) 124
inhibition (116) 116
nitric-oxide synthase (114) 114
disease models, animal (111) 111
nitric oxide synthase type i (110) 110
nitric oxide - metabolism (108) 108
antineoplastic combined chemotherapy protocols - therapeutic use (107) 107
brain (104) 104
nitric oxide synthase - metabolism (104) 104
imidazoles - administration & dosage (103) 103
expression (101) 101
antineoplastic agents - administration & dosage (100) 100
time factors (99) 99
indazoles - chemistry (98) 98
cell line, tumor (96) 96
axitinib (95) 95
rat (91) 91
nitric oxide synthase (89) 89
nitric oxide - physiology (87) 87
in-vivo (84) 84
l-arginine (84) 84
treatment outcome (84) 84
analysis (81) 81
chemistry, medicinal (79) 79
protein kinase inhibitors - administration & dosage (78) 78
biochemistry & molecular biology (77) 77
carcinoma, renal cell - drug therapy (77) 77
blood pressure - drug effects (76) 76
chemotherapy (76) 76
imidazoles - therapeutic use (75) 75
antineoplastic agents - therapeutic use (73) 73
antineoplastic agents - adverse effects (72) 72
physiology (72) 72
arginine - pharmacology (71) 71
antineoplastic agents - pharmacology (69) 69
drug synergism (69) 69
lonidamine (69) 69
nitric oxide synthase type i - antagonists & inhibitors (69) 69
kidney neoplasms - drug therapy (67) 67
imidazoles - adverse effects (64) 64
in vitro techniques (63) 63
neoplasms - drug therapy (63) 63
sorafenib (62) 62
synthase (62) 62
drug administration schedule (61) 61
neurons (61) 61
signal transduction - drug effects (61) 61
protein kinase inhibitors - pharmacology (60) 60
research (60) 60
xenograft model antitumor assays (60) 60
activation (58) 58
care and treatment (58) 58
granisetron (56) 56
inhibitor (56) 56
structure-activity relationship (56) 56
angiogenesis (55) 55
article (55) 55
disease-free survival (55) 55
imidazoles - pharmacology (54) 54
cell proliferation - drug effects (53) 53
mice, inbred c57bl (53) 53
protein kinase inhibitors - therapeutic use (53) 53
cells (51) 51
enzyme inhibitors - administration & dosage (51) 51
sunitinib (51) 51
cell biology (50) 50
apoptosis (49) 49
indazoles - blood (49) 49
l-name (49) 49
nitric oxide synthase type i - metabolism (49) 49
pharmacology (49) 49
antineoplastic combined chemotherapy protocols - adverse effects (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1348) 1348
Japanese (12) 12
Russian (9) 9
Italian (6) 6
Chinese (5) 5
German (3) 3
French (2) 2
Hungarian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
Toxicities associated with vascular endothelial growth factor–targeted therapies can often compromise clinical benefit in patients with metastatic renal cell... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
PLOS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0125021
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance.... 
COLON-CANCER | MELANOMA | MEK INHIBITION | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | SYNTHETIC LETHAL INTERACTION | RESISTANCE | BRAF | KINASE INHIBITOR | BETA-CATENIN | EGFR | Triazoles - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Aza Compounds - pharmacology | Cell Line, Tumor - drug effects | Indazoles - administration & dosage | Quinolines - administration & dosage | Indoles - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Melanoma - genetics | Indoles - pharmacology | Pyrimidinones - pharmacology | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Aza Compounds - administration & dosage | Imidazoles - pharmacology | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | beta Catenin - metabolism | beta Catenin - genetics | Indazoles - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Triazoles - pharmacology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Oxazoles - administration & dosage | Oximes - pharmacology | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Oxazoles - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - pharmacology | Sulfonamides - administration & dosage | Drug therapy, Combination | Drug resistance | Drug therapy | Health aspects | Analysis | Melanoma
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 04/2016, Volume 32, Issue 4, pp. 741 - 747
Journal Article
Angiogenesis, ISSN 0969-6970, 10/2014, Volume 17, Issue 4, pp. 805 - 821
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer worldwide. Recently, it has been found that about 40 % of patients with CRC have mutations... 
K - RAS | Tyrosine kinase inhibitor | Oncology | Aflibercept | Biomedicine general | Cell Biology | Bevacizumab | Biomedicine | Cancer Research | Ophthalmology | Cardiology | Antiangiogenic | Metastatic colorectal cancer | K-RAS | 1ST-LINE TREATMENT | IRINOTECAN PLUS | ANTI-VEGF | INFUSIONAL FLUOROURACIL | BEVACIZUMAB PLUS FLUOROURACIL | PHASE-II TRIAL | MUTATION STATUS | ORAL FLUOROPYRIMIDINES | PERIPHERAL VASCULAR DISEASE | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Prognosis | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Capecitabine | Colorectal Neoplasms - genetics | Humans | Recombinant Fusion Proteins - therapeutic use | Imidazoles - administration & dosage | Vascular Endothelial Growth Factor A - metabolism | Indazoles - administration & dosage | Indoles - administration & dosage | Organoplatinum Compounds - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Fluorouracil - administration & dosage | Pyrroles - administration & dosage | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Quinazolines - administration & dosage | Camptothecin - analogs & derivatives | Pharmacogenetics | Antibodies, Monoclonal, Humanized - therapeutic use | Pyridines - administration & dosage | Fluorouracil - analogs & derivatives | Signal Transduction | Deoxycytidine - administration & dosage | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, ras | Deoxycytidine - analogs & derivatives | Protein-Tyrosine Kinases - antagonists & inhibitors | Complications and side effects | Colorectal cancer | Physiological aspects | Dosage and administration | Genetic aspects | Angiogenesis inhibitors | Research | Drug therapy | Renin-angiotensin system
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2017, Volume 15, Issue 6, pp. 1095 - 1102
Background: Epistaxis and gastrointestinal (GI) tract hemorrhages are common symptoms of aged hereditary hemorrhagic telangiectasia (HHT) patients that result... 
arteriovenous malformation | activin receptors | telangiectasia | angiogenesis inhibitors | hereditary hemorrhagic | anemia | ARTERIOVENOUS-MALFORMATIONS | BEVACIZUMAB | RANDOMIZED CLINICAL-TRIAL | SORAFENIB | CANCER | RENAL-CELL CARCINOMA | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ERLOTINIB | Niacinamide - analogs & derivatives | Telangiectasia, Hereditary Hemorrhagic - genetics | Vascular Endothelial Growth Factor A - metabolism | Indazoles - administration & dosage | Wound Healing | Anemia - genetics | Anemia - drug therapy | Angiogenesis Inhibitors - therapeutic use | Arteriovenous Malformations | Tyrosine - chemistry | Disease Models, Animal | Administration, Oral | Gastrointestinal Hemorrhage | Pyrimidines - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Activin Receptors, Type I - metabolism | Telangiectasia, Hereditary Hemorrhagic - drug therapy | Mice, Knockout | Niacinamide - administration & dosage | Skin - blood supply | Animals | Image Processing, Computer-Assisted | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Mice | Administration, Topical | Hemoglobins - analysis | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Viral antibodies | Tyrosine | Telangiectasis | Endothelial growth factors | Anemia | Analysis | Antibodies | Phenols | Hemoglobin | Angiogenesis inhibitors | Animal models | Oral administration | Wounds | Hereditary hemorrhagic telangiectasia | Hemorrhage | Bleeding | Intestine | Skin | Activin | Vascular endothelial growth factor | Protein-tyrosine kinase
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2008, Volume 51, Issue 18, pp. 5522 - 5532
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2007, Volume 6, Issue 7, pp. 2012 - 2021
With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy... 
kinase inhibitor | Pharmacodynamics | pazopanib | angiogenesis | VEGF | TARGET | ONCOLOGY | FACTOR RECEPTORS | EXPRESSION | CANCER | TUMORS | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Pyrimidines - blood | Humans | Fibroblast Growth Factor 2 - pharmacology | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Sulfones - pharmacology | Neovascularization, Pathologic - pathology | Phosphotyrosine - metabolism | Dose-Response Relationship, Drug | Sulfonamides - blood | Inhibitory Concentration 50 | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cornea - pathology | Phosphorylation - drug effects | Sulfones - blood | Vascular Endothelial Growth Factor A - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Pyrimidines - pharmacology | Sulfones - pharmacokinetics | Sulfonamides - pharmacology | Protein Kinase Inhibitors - blood | Sulfonamides - pharmacokinetics | Indazoles - pharmacology | Protein Kinase Inhibitors - administration & dosage | Indazoles - blood | Animals | Indazoles - pharmacokinetics | Cell-Free System | Mice, Nude | Antineoplastic Agents - blood | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Mice | Protein Kinase Inhibitors - pharmacology | Sulfonamides - administration & dosage | Sulfones - administration & dosage
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 186 - 196
The phosphatidylinositol 3-kinase (PI3K) pathway is a potential therapeutic target in non–small cell lung cancer (NSCLC). This study aimed to evaluate the... 
First-line NSCLC | Metastatic NSCLC | Non–small cell lung | Paclitaxel | Carboplatin | Phosphatidylinositol 3-kinase | Pemetrexed | Cisplatin | Bevacizumab | Front-line NSCLC | SUBTYPES | PI3K INHIBITORS | KINASE | SENSITIVITY | OPPORTUNITIES | LESSONS | GDC-0941 | POTENT | ONCOLOGY | PRECLINICAL MODELS | PATHWAY | Non-small cell lung | Lung Neoplasms - drug therapy | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Phosphatidylinositol 3-Kinases - metabolism | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Cisplatin - administration & dosage | Carboplatin - adverse effects | Drug Dosage Calculations | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Protein Kinase Inhibitors - pharmacokinetics | Lung Neoplasms - enzymology | Bevacizumab - administration & dosage | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Sulfonamides - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Indazoles - pharmacokinetics | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Pemetrexed - administration & dosage | Sulfonamides - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Indazoles - adverse effects | Neoplasm Staging | Sulfonamides - administration & dosage | Antimitotic agents | Care and treatment | Safety and security measures | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Antineoplastic agents
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 07/2013, Volume 119, Issue 14, pp. 2555 - 2563
Journal Article
Epilepsy Research, ISSN 0920-1211, 2010, Volume 89, Issue 2, pp. 295 - 302
Summary Lithium is still the mainstay in the treatment of affective disorders as a mood stabilizer. Lithium also shows some anticonvulsant properties. While... 
Neurology | Pentylenetetrazole | Mice | Lithium chloride | Nitric oxide-cGMP pathway | Clonic seizure threshold | HIPPOCAMPAL DAMAGE | NERVOUS-SYSTEM | CARBAMAZEPINE | FORCED SWIMMING TEST | CLINICAL NEUROLOGY | CEREBELLAR GRANULE CELLS | SYNTHASE | PROCONVULSANT | L-ARGININE | RAT-BRAIN | NITRERGIC SYSTEM | Piperazines - administration & dosage | Seizures - drug therapy | Nitric Oxide Synthase - antagonists & inhibitors | Anticonvulsants - administration & dosage | Male | Indazoles - administration & dosage | Purines - administration & dosage | NG-Nitroarginine Methyl Ester - administration & dosage | Sulfones - pharmacology | Anticonvulsants - pharmacology | Arginine - administration & dosage | Seizures - chemically induced | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Sildenafil Citrate | Enzyme Inhibitors - pharmacokinetics | Lithium Chloride - pharmacology | Disease Models, Animal | NG-Nitroarginine Methyl Ester - pharmacology | Purines - pharmacology | Injections, Intraperitoneal | Lithium Chloride - administration & dosage | Phosphodiesterase Inhibitors - pharmacology | Treatment Outcome | Methylene Blue - pharmacology | Piperazines - pharmacology | Indazoles - pharmacology | Methylene Blue - administration & dosage | Phosphodiesterase Inhibitors - administration & dosage | Animals | Cyclic GMP - metabolism | Arginine - pharmacology | Convulsants | Nitric Oxide - metabolism | Sulfones - administration & dosage
Journal Article
Journal Article